| Objective:To observe the clinical efficacy of Jianpi Huatan Sanjie Decoction combined with SOX chemotherapy in the treatment of advanced colorectal cancer,to explore the role of Jianpi Huatan Sanjie Decoction in the treatment of advanced colorectal cancer,and to evaluate its clinical valueMethods:Selected into the standard of 53 patients with advanced colorectal cancer as the research object,the treatment group 28 cases(Jianpi Huatan Sanjie Decoction Combined with SOX Chemotherapy Regimen),the control group,25 cases(only)the SOX regimen for six weeks after comparing two groups in solid tumor efficacy,TCM syndrome score,serum tumor markers,immune function,common toxic and side effects,peripheral neurotoxicity and KPS score between the two groups were compared to evaluate the role of Jianpi Huatan Sanjie Decoction in advanced colorectal cancer..Results:Efficacy evaluation of solid tumor:after 6 weeks of treatment,there were 0 cases of CR,11 cases of PR,15 cases of SD and 2 cases of PD in the treatment group.In the control group,there were 0 cases of CR,9 cases of PR,14 cases of SD and 2 cases of PD.The effective rate of disease in treatment group and control group was respectively 39.29%and 36%,?2=0.061,P=0.805;The disease control rate of the treatment group and the control group were 92.86%and 92%,respectively,?2=0.00,P=1.00.There was no significant difference in effective rate and disease control rate between the two groups(P>0.05)Efficacy evaluation of TCM syndromes:after treatment,the efficacy score of TCM syndromes of the patients was analyzed.The effective rate of the treatment group was 85.71%and the effective rate of the control group was 60%,and the difference was statistically significant(P<0.05).Evaluation of serum tumor markers:after 6 weeks of treatment,there was no significant difference in CEA between the treatment group and the control group(Z=-0.588,P=0.557>0.05),and no significant difference in CA199(Z=-0.820,P=0.412>0.05).Both CEA and CA199 in the treatment group decreased after treatment compared with before treatment,and the difference between CEA and CA199 before and after treatment was statistically significant(Z=-4.252,P=0.000<0.05)and CA199 was statistically significant(Z=-3.460,P=0.001<0.05).In the control group,both CEA and CA199 decreased after treatment compared with before treatment.After test,CEA difference before and after treatment was statistically significant(Z=-2.623,P=0.009<0.05),and CA199 difference was statistically significant(Z=-3.538,P=0.000<0.05).Comparison of immune function:after treatment,there were significant differences in CD3+,CD4+,CD8+ and CD4+/CD8+between the treatment group and the control group(P were 0.025,0.001,0.000 and 0.000,respectively,all<0.05).After treatment,CD3+,CD4+,CD4+/CD8+were all increased and CD8+was decreased in the treatment group compared with before treatment(P<0.05).CD3+,CD4+,CD8+,CD4+/CD8+were slightly higher in the control group after treatment than before treatment,with no statistically significant difference(P were 0.091,0.270,0.060,0.893,all>0.05).Evaluation of common toxic and side effects:the incidence of leukocyte,hemoglobin,nausea,vomiting and diarrhea in the treatment group was significantly lower than that in the control group,with significant difference(P<0.05),while the incidence of toxic and side effects in the other two groups was not significantly different(P>0.05).Evaluation of peripheral neurotoxicity:after 6 weeks of treatment,the neurotoxicity of the two groups was observed.The results showed that the incidence of neurotoxicity in the treatment group was 10.71%,and that in the control group was 36.00%.The difference between the two groups was statistically significant(P<0.05).Quality of life comparison:after treatment,the KPS score of the two groups was tested,Z=-2.116,P=0.034,the difference was statistically significant(P<0.05).In the treatment group,12 patients improved,stabilized 14,and deteriorated 2,with a stability rate of 92.86%;in the control group,4 patients improved,stabilized 12,and deteriorated 9,with a stability rate of 64.00%,P=0.010,the difference was statistically significant(P<0.05).Conclusion:Jianpi Huatan Sanjie Decoction combined with SOX chemotherapy regimen is applied to advanced colorectal cancer,which can improve patients' TCM symptoms,alleviate the myelosuppression and gastrointestinal reactions caused by chemotherapy,reduce the incidence of peripheral neurotoxic reactions,improve patients' immune function and improve their quality of life. |
PDF Full Text Request